share_log

Molecular Data And Aurora Cannabis Among The List Of The Most Active Winners And Losers Of Monday’s US Session

Molecular Data And Aurora Cannabis Among The List Of The Most Active Winners And Losers Of Monday’s US Session

摩貝和奧羅拉大麻在週一美國時段最活躍的贏家和輸家之列
Via news ·  2022/05/31 05:35

(VIANEWS) – Another day of trading has ended and here's today's list of stocks that have had significant trading activity in the US session.

(VIANEWS)-又一個交易日結束了,以下是今天在美國交易時段有重大交易活動的股票名單。

The three most active and biggest winners today are Molecular Data, ENDRA Life Sciences, and PAVmed.

如今最活躍和最大的三家贏家是摩貝、ENDRA生命科學和PAVmed。

Rank Financial Asset Price Change Updated (EST)
1 Molecular Data (MKD) 0.94 828.5% 2022-05-30 01:15:49
2 ENDRA Life Sciences (NDRAW) 0.03 150% 2022-05-30 05:09:06
3 PAVmed (PAVMW) 0.03 105.67% 2022-05-30 14:07:21
4 Oncternal Therapeutics (ONCT) 1.54 88.08% 2022-05-30 10:17:06
5 National Energy Services Reunited Corp. (NESRW) 1.04 56.18% 2022-05-30 05:11:06
6 Meten EdtechX Education Group Ltd. (METXW) 0.10 41.51% 2022-05-30 00:07:18
7 Vmware (VMW) 129.26 36.13% 2022-05-30 09:24:25
8 Southwestern Energy (SWN) 9.32 34.68% 2022-05-30 09:21:08
9 Merus N.V. (MRUS) 18.53 32.55% 2022-05-30 03:10:06
10 Antero Resources (AR) 44.74 27.21% 2022-05-30 09:11:25
職級 金融資產 價格 變化 更新(美國東部夏令時)
1 摩貝(Sequoia Capital) 0.94 828.5% 2022-05-30 01:15:49
2 ENDRA生命科學(NDRAW) 0.03 150% 2022-05-30 05:09:06
3 PAVmed(PAVMW) 0.03 105.67% 2022-05-30 14:07:21
4 腫瘤治療學(ONCT) 1.54 88.08% 2022-05-30 10:17:06
5 國家能源服務聯合公司(NESRW) 1.04 56.18% 2022-05-30 05:11:06
6 美聯國際教育集團有限公司(METXW) 0.10 41.51% 2022-05-30 00:07:18
7 VMware(VMW) 129.26 36.13% 2022-05-30 09:24:25
8 西南能源(SWN) 9.32 34.68% 2022-05-30 09:21:08
9 Merus N.V.(MRU) 18.53 32.55% 2022-05-30 03:10:06
10 Antero Resources(AR) 44.74 27.21% 2022-05-30 09:11:25

The three most active and biggest losers today are Aurora Cannabis, Ironwood Investment Management, LLC, and Aurora Cannabis.

今天最活躍和最大的三個輸家是Aurora Cannabis、Ironwood Investment Management LLC和Aurora Cannabis。

Rank Financial Asset Price Change Updated (EST)
1 Aurora Cannabis (ACB) 1.68 -44.74% 2022-05-30 09:25:53
2 Ironwood Investment Management, LLC (ACB) 1.68 -44.74% 2022-05-30 09:25:53
3 Aurora Cannabis (ACB) 1.68 -44.74% 2022-05-30 09:25:53
4 Ironwood Investment Management, LLC (ACB) 1.68 -44.74% 2022-05-30 09:25:53
5 Snap (SNAP) 15.58 -32.84% 2022-05-30 09:26:01
6 Liquidia Technologies (LQDA) 4.07 -29.58% 2022-05-29 21:11:44
7 NeuroMetrix (NURO) 4.10 -25.45% 2022-05-30 09:06:40
8 Medigus Ltd. (MDGSW) 0.24 -22.93% 2022-05-29 23:11:08
9 NeuroBo Pharmaceuticals (NRBO) 0.43 -22.21% 2022-05-30 07:14:12
10 Canopy Growth (CGC) 4.88 -16.87% 2022-05-30 09:15:57
職級 金融資產 價格 變化 更新(美國東部夏令時)
1 極光大麻(Aurora Cannabis) 1.68 -44.74% 2022-05-30 09:25:53
2 鐵木投資管理有限責任公司(ACB) 1.68 -44.74% 2022-05-30 09:25:53
3 極光大麻(Aurora Cannabis) 1.68 -44.74% 2022-05-30 09:25:53
4 鐵木投資管理有限責任公司(ACB) 1.68 -44.74% 2022-05-30 09:25:53
5 捕捉(SNAP) 15.58 -32.84% 2022-05-30 09:26:01
6 Liqudia Technologies(LQDA) 4.07 -29.58% 2022-05-29 21:11:44
7 神經間質(Neurometrix) 4.10 -25.45% 2022-05-30 09:06:40
8 邁迪格斯有限公司(Medigus Ltd.) 0.24 -22.93% 2022-05-29 23:11:08
9 NeuroBo製藥公司(NRBO) 0.43 -22.21% 2022-05-30 07:14:12
10 冠層生長(CGC) 4.88 -16.87% 2022-05-30 09:15:57

Most Active Winners today

今天最活躍的獲獎者

1. Molecular Data (MKD) – 828.5%

1.摩貝(MKD)--828.5%

Through its subsidiaries, Molecular Data Inc. operates in China's chemical ecommerce market. Through its integrated solutions, the company provides a technology-driven platform to connect participants across the entire chemical value chain. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites that are intended to solve pain points for participants in the traditional chemical industry. It offers its online solutions via molbase.com, molbase.cn and Moku Data Weixin accounts; Chemical Community app; as well other platforms. Shanghai is the headquarters of this company, which was established in 2013.

通過旗下子公司,摩貝在中國化工電子商務市場開展業務。通過其集成解決方案,該公司提供了一個技術驅動的平臺,將整個化學品價值鏈的參與者聯繫起來。它提供電子商務解決方案、財務解決方案、倉儲和物流解決方案以及軟件即服務套件,旨在為傳統化工行業的參與者解決痛點。它通過molbase.com、molbase.cn和Moku Data微信賬户;化學社區APP;以及其他平臺提供在線解決方案。上海是這家成立於2013年的公司的總部。

NASDAQ ended the session with Molecular Data rising 828.5% to $0.94 on Monday, after two successive sessions in a row of losses. NASDAQ rose 3.33% to $12,131.13, after three successive sessions in a row of gains, on what was a very positive trend trading session today.

納斯達克週一收盤上漲828.5%,至0.94美元,此前連續兩個交易日下跌。納斯達克在連續三個交易日上漲後,上漲3.33%,至12,131.13美元,今日是一個非常積極的交易日。

Volume

Today's last reported volume for Molecular Data is 728912 which is 44.67% below its average volume of 1317630.

今日摩貝最新公佈的成交量為728912,較其平均成交量1317630低44.67%。

Molecular Data's last close was $0.94, 94.06% under its 52-week high of $15.75.

摩貝收盤報0.94美元,較其52周高點15.75美元低94.06%。

Molecular Data's Revenue

摩貝的營收

Year-on-year quarterly revenue growth declined by 67.1%, now sitting on 4.62B for the twelve trailing months.

與去年同期相比,季度收入增長下降了67.1%,連續12個月保持在46.2億美元。

Molecular Data's Stock Yearly Top and Bottom Value

摩貝股票年度最高值和最低值

Molecular Data's stock is valued at $0.94 at 17:32 EST, way below its 52-week high of $15.75 and way higher than its 52-week low of $0.77.

美國東部時間17:32,摩貝的估值為0.94美元,遠低於其52周高點15.75美元,遠高於其52周低點0.77美元。

Molecular Data's Moving Average

摩貝移動平均線

Molecular Data's worth is way below its 50-day moving average of $2.17 and way below its 200-day moving average of $3.74.

摩貝的市值遠低於50日移動均線切入位2.17美元,也遠低於200日移動均線切入位3.74美元。

More news about Molecular Data.

更多關於摩貝的新聞。

2. ENDRA Life Sciences (NDRAW) – 150%

2.ENDRA生命科學(NDRAW)-150%

NASDAQ ended the session with ENDRA Life Sciences rising 150% to $0.03 on Monday while NASDAQ rose 3.33% to $12,131.13.

納斯達克週一收盤時上漲150%,至0.03美元,納斯達克上漲3.33%,至12,131.13美元。

ENDRA Life Sciences's last close was $0.03, 0% under its 52-week high of $0.03.

ENDRA Life Sciences的最後收盤價為0.03美元,較其52周高點0.03美元低了0%。

ENDRA Life Sciences's Stock Yearly Top and Bottom Value

ENDRA生命科學公司股票年度最高和最低值

ENDRA Life Sciences's stock is valued at $0.03 at 17:32 EST, way below its 52-week low of $0.01.

美國東部時間17:32,ENDRA Life Science的股價為0.03美元,遠低於其52周低點0.01美元。

More news about ENDRA Life Sciences.

更多關於ENDRA生命科學的新聞。

3. PAVmed (PAVMW) – 105.67%

3.PAVmed(PAVMW)--105.67%

PAVmed Inc. is a United States-based medical device company. CarpX is a percutaneous device that treats carpal tunnel syndrome. EsoCheck (esophageal cell collection instrument for early detection of Barrett's Esophagus or adenocarcinoma) are the company's leading products. The company's products include EsoGuard (a molecular diagnostic DNA test for the esophageal); EsoCure (an esophageal ablation tool to treat dysplastic BE); NextFlo (a disposable infusion platform tech); PortIO (an implantable intraosseous access device); DisappEAR (a resorbable pediatric tube), NextCath, and Caldus. In April 2015, the company changed its name from PAXmed Inc. to PAVmed Inc. PAVmed Inc. was founded in 2014. It is located in New York, New York.

PAVmed Inc.是一家總部位於美國的醫療器械公司。CarpX是一種治療腕管綜合徵的經皮設備。EsoCheck(用於早期檢測Barrett‘s食道或腺癌的食道細胞採集儀)是該公司的主導產品。該公司的產品包括EsoGuard(一種針對食道的分子診斷DNA測試);EsoCure(一種用於治療BE發育不良的食道消融工具);NextFlo(一次性輸液平臺技術);Portio(一種植入式骨內接入設備);Send(一種可吸收的兒科導管)、NextCath和Caldus。2015年4月,該公司從PAXmed Inc.更名為PAVmed Inc.。PAVmed Inc.成立於2014年。它位於紐約,紐約州。

NASDAQ ended the session with PAVmed jumping 105.67% to $0.03 on Monday, following the last session's downward trend. NASDAQ jumped 3.33% to $12,131.13, after three consecutive sessions in a row of gains, on what was a very positive trend trading session today.

納斯達克週一收盤時上漲105.67%,至0.03美元,延續上個交易日的下跌趨勢。納斯達克在連續三個交易日上漲後,躍升3.33%,至12,131.13美元,今日是非常積極的交易時段。

Volume

Today's last reported volume for PAVmed is 32626 which is 397.12% above its average volume of 6563.

今天最新報告的PAVmed成交量為32626台,比6,563台的平均成交量高397.12%。

PAVmed's last close was $0.03, 99.39% under its 52-week high of $4.74.

PAVmed最新收盤報0.03美元,較52周高位4.74美元低99.39%。

PAVmed's Stock Yearly Top and Bottom Value

PAVmed的股票年度最高和最低價值

PAVmed's stock is valued at $0.03 at 17:32 EST, way under its 52-week high of $4.74 and way above its 52-week low of $0.02.

在美國東部時間17:32,PAVmed的股價為0.03美元,遠低於4.74美元的52周高點,也遠高於0.02美元的52周低點。

PAVmed's Moving Average

PAVmed移動平均線

PAVmed's value is way under its 50-day moving average of $0.21 and way under its 200-day moving average of $1.66.

PAVmed的價值遠低於50日移動均線切入位0.21美元,也遠低於200日移動均線切入位1.66美元。

More news about PAVmed.

更多關於PAVmed的新聞。

4. Oncternal Therapeutics (ONCT) – 88.08%

4.腫瘤治療(ONCT)--88.08%

Oncternal Therapeutics, Inc. is a biopharmaceutical company at the clinical stage. It focuses its efforts on developing oncology treatments for cancers that have a critical unmet medical demand. The company's pipeline also includes cirmtuzumab (an investigational monoclonal anti-inflammatory antibody) that is currently being tested in a Phase 1/2 clinical study in conjunction with ibrutinib to treat patients with B cell lymphoid malignancies such as mantle cells lymphoma or chronic lymphocytic Leukemia. A chimeric antigen receptor-like T cell therapy is being developed by the company. It targets Receptor Tyrosine Kinase-like Orphan Receptor 1. This treatment could be used to treat solid tumors as well as other hematologic diseases. It is also developing TK216 an investigational small molecule to inhibit the E26 Transformation Specific Family of oncoproteins. Oncternal Therapeutics, Inc. holds license agreements with Georgetown University, Shanghai Pharmaceutical (USA), Inc., Selexis S.A., and the University of Tennessee Research Foundation. San Diego is the company's headquarters.

Onctal Treateutics公司是一家處於臨牀階段的生物製藥公司。它將重點放在為有嚴重未得到滿足的醫療需求的癌症開發腫瘤學治療上。該公司正在研發的藥物還包括Cirmtuzumab(一種研究中的單抗),目前正在與ibrutinib一起進行1/2期臨牀研究,用於治療套細胞淋巴瘤或慢性淋巴細胞白血病等B細胞淋巴系統惡性腫瘤患者。該公司正在開發一種嵌合抗原受體樣T細胞療法。它針對受體酪氨酸激酶樣孤兒受體1。這種治療方法可以用於治療實體瘤和其他血液病。該公司還在開發TK216,這是一種研究用小分子,可以抑制E26轉化特異性癌蛋白家族。Onctal治療公司與喬治敦大學、上海醫藥(美國)有限公司、Selexis S.A.和田納西大學研究基金會簽訂了許可協議。聖地亞哥是該公司的總部。

NASDAQ ended the session with Oncternal Therapeutics rising 88.08% to $1.54 on Monday while NASDAQ jumped 3.33% to $12,131.13.

週一收盤時,納斯達克股價上漲88.08%,至1.54美元,納斯達克上漲3.33%,至12,131.13美元。

Volume

Today's last reported volume for Oncternal Therapeutics is 20994200 which is 3155.5% above its average volume of 644884.

今天,Oncent Treateutics的最新報告數量為20994200,比其平均數量644884高出3155.5%。

Oncternal Therapeutics 's last close was $1.54, 73.81% below its 52-week high of $5.88.

Oncent Treateutics的最後收盤價為1.54美元,較5.88美元的52周高點低73.81%。

Oncternal Therapeutics 's Sales

Oncent Treateutics的銷售

Oncternal Therapeutics 's sales growth is a negative 47.9% for the ongoing quarter and a decline by 62.3% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 43.8% and a negative 21.1%, respectively.

Oncent Treateutics公司當前季度的銷售額增長為負47.9%,下一季度為下降62.3%。該公司對當前季度和下一季度的增長預期分別為負43.8%和負21.1%。

Oncternal Therapeutics 's Revenue

Oncent Treateutics的收入

Year-on-year quarterly revenue growth declined by 0.3%, now sitting on 4.31M for the twelve trailing months.

與去年同期相比,季度收入增長下降了0.3%,連續12個月增長431萬。

Oncternal Therapeutics 's Stock Yearly Top and Bottom Value

Oncent Treatetics的年度股票最高和最低價值

Oncternal Therapeutics 's stock is valued at $1.54 at 17:32 EST, way under its 52-week high of $5.88 and way higher than its 52-week low of $0.69.

截至美國東部時間17點32分,Oncent Treeutics的股價為1.54美元,遠低於5.88美元的52周高點,也遠高於0.69美元的52周低點。

Oncternal Therapeutics 's Moving Average

Oncent Treateutics的移動平均數

Oncternal Therapeutics 's worth is way higher than its 50-day moving average of $1.11 and way under its 200-day moving average of $2.55.

Onctal Treateutics的市值遠高於其50日移動均線1.11美元,也遠低於其200日移動均線2.55美元。

More news about Oncternal Therapeutics .

更多關於腫瘤學治療的新聞。

5. National Energy Services Reunited Corp. (NESRW) – 56.18%

5.國家能源服務聯合公司(NESRW)-56.18%

NASDAQ ended the session with National Energy Services Reunited Corp. rising 56.18% to $1.04 on Monday, after five sequential sessions in a row of losses. NASDAQ jumped 3.33% to $12,131.13, after three sequential sessions in a row of gains, on what was a very bullish trend trading session today.

納斯達克收盤時上漲56.18%,至1.04美元,此前連續五個交易日下跌。納斯達克在連續三個交易日上漲後躍升3.33%,至12,131.13美元,今日是一個非常看漲的交易日。

National Energy Services Reunited Corp.'s last close was $1.04, 0% under its 52-week high of $1.04.

National Energy Services reunded Corp.收盤報1.04美元,較1.04美元的52周高點低0%。

National Energy Services Reunited Corp.'s Stock Yearly Top and Bottom Value

國家能源服務公司股票年度最高和最低價值

National Energy Services Reunited Corp.'s stock is valued at $1.04 at 17:32 EST, under its 52-week low of $1.04.

美國東部時間17點32分,National Energy Services reunated Corp.的股價為1.04美元,低於1.04美元的52周低點。

More news about National Energy Services Reunited Corp..

更多關於國家能源服務聯合公司的新聞。

6. Meten EdtechX Education Group Ltd. (METXW) – 41.51%

6.美聯國際教育集團控股有限公司--41.51%

NASDAQ ended the session with Meten EdtechX Education Group Ltd. jumping 41.51% to $0.10 on Monday, after five sequential sessions in a row of losses. NASDAQ rose 3.33% to $12,131.13, after three successive sessions in a row of gains, on what was a very bullish trend exchanging session today.

納斯達克週一收漲41.51%,至0.1美元,此前連續五個交易日下跌。納斯達克在連續三個交易日上漲後,上漲3.33%,至12,131.13美元,這是一個非常看漲的趨勢交流時段。

Meten EdtechX Education Group Ltd.'s last close was $0.10, 2.36% under its 52-week high of $0.10.

美聯國際教育集團收盤報0.10美元,較0.10美元的52周高點低2.36%。

Meten EdtechX Education Group Ltd.'s Stock Yearly Top and Bottom Value

美聯國際教育集團股份有限公司股票年度最高值和最低值

Meten EdtechX Education Group Ltd.'s stock is valued at $0.10 at 17:32 EST, below its 52-week high of $0.10 and above its 52-week low of $0.09.

美國東部時間17:32,美聯國際教育集團股份有限公司的股票估值為0.1美元,低於0.10美元的52周高點,高於0.09美元的52周低點。

More news about Meten EdtechX Education Group Ltd..

更多關於美聯國際教育集團有限公司的新聞。

7. Vmware (VMW) – 36.13%

7.VMware(VMW)-36.13%

VMware, Inc. offers software for hybrid cloud, multicloud, modern apps, security, networking, and digital workspaces both in the United States as well internationally. VMware vSphere is a platform that allows users to install hypervisor. This layer of software is located between the operating system's hardware and operates to allow compute virtualization. It also offers cloud management products to help businesses automate, programmable provision, and monitor their applications. Customers can also access networking products and services, as well as storage and availability products that include data storage options and protection. It also offers VMware Cloud Foundation. This platform combines compute, storage and networking technologies with cloud administration to create an integrated stack that delivers enterprise-ready cloud infrastructure in private and public clouds. It also offers hybrid cloud computing services, including VMware Cloud Foundation, VMware Cloud Provider Program and VMware Cloud Services. Workspace ONE delivers and manages all applications on every device. This includes pivotal cloud findry, pivotal labs and heptio as well as access control, multi-platform management and application management. It sells products via distributors, resellers and system vendors. VMware, Inc. is a strategic partner with Amazon Web Services, which will build and deliver an integrated solution. SNC-Lavalin, on the other hand, will provide a digital collaboration platform to facilitate project delivery. It was founded in 1998, and its headquarters are in Palo Alto (California). VMware, Inc., is a subsidiary Dell Technologies Inc.

VMware,Inc.在美國和國際上提供用於混合雲、多雲、現代應用程序、安全、網絡和數字工作空間的軟件。VMware vSphere是一個允許用户安裝虛擬機管理程序的平臺。這一層軟件位於操作系統的硬件之間,用於實現計算虛擬化。它還提供雲管理產品,幫助企業實現應用程序的自動化、可編程配置和監控。客户還可以訪問網絡產品和服務,以及包括數據存儲選項和保護的存儲和可用性產品。它還提供VMware Cloud Foundation。該平臺將計算、存儲和網絡技術與雲管理相結合,創建了一個集成堆棧,可在私有云和公共雲中提供企業就緒型雲基礎設施。它還提供混合雲計算服務,包括VMware Cloud Foundation、VMware Cloud Provider Program和VMware Cloud Services。Workspace One交付並管理每台設備上的所有應用程序。這包括Pivotal雲框架、Pivotal實驗室和Heptio以及訪問控制、多平臺管理和應用程序管理。它通過分銷商、轉售商和系統供應商銷售產品。VMware,Inc.是亞馬遜網絡服務公司的戰略合作伙伴,亞馬遜網絡服務公司將構建和提供集成解決方案。另一方面,SNC-Lavalin將提供一個數字協作平臺,以促進項目交付。它成立於1998年,總部設在加利福尼亞州的帕洛阿爾託。VMware,Inc.是戴爾技術公司的子公司。

NYSE ended the session with Vmware rising 36.13% to $129.26 on Monday while NYSE jumped 1.78% to $15,942.62.

週一紐約證交所收盤時,VMware股價上漲36.13%,至129.26美元,紐約證交所股價上漲1.78%,至15,942.62美元。

Volume

Today's last reported volume for Vmware is 5826070 which is 194.03% above its average volume of 1981450.

今天,Vmware的最新成交量為5826070,比1981450的平均成交量高出194.03%。

Vmware's last close was $129.26, 22.98% under its 52-week high of $167.83.

VMware的最後收盤價為129.26美元,較其52周高點167.83美元低22.98%。

The company's growth estimates for the present quarter and the next is a negative 10.8% and a negative 4%, respectively.

該公司對當前季度和下一季度的增長預期分別為負10.8%和負4%。

Vmware's Revenue

VMware的收入

Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 12.85B for the twelve trailing months.

季度營收同比增長7.2%,連續12個月達到128.5億歐元。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Vmware's stock is considered to be oversold (<=20).

VMware的股票被認為是超賣的(

Vmware's Stock Yearly Top and Bottom Value

VMware的股票年度最高和最低值

Vmware's stock is valued at $129.26 at 17:32 EST, way below its 52-week high of $167.83 and way above its 52-week low of $91.53.

美國東部時間17:32時,VMware的股票估值為129.26美元,遠低於52周高點167.83美元,遠高於52周低點91.53美元。

Vmware's Moving Average

VMware移動平均線

Vmware's value is way above its 50-day moving average of $109.28 and higher than its 200-day moving average of $127.43.

Vmware的價值遠高於其50日移動均線109.28美元,也高於其200日移動均線127.43美元。

More news about Vmware.

更多關於VMware的新聞。

8. Southwestern Energy (SWN) – 34.68%

8.西南能源(SWN)-34.68%

Southwestern Energy Company is an independent energy company that specializes in exploration, development and production of natural and oil in the United States. The company operates in Exploration and Production and Marketing segments. It focuses its efforts on developing unconventional natural gas reserves in West Virginia and Pennsylvania. It had 173,994 acres of Northeast Appalachia and 287,693 acres in Southwest Appalachia as of December 31, 2019. Its proved oil and natural gas reserves, as well as NGLs and natural gas reserves, are estimated at 12,721 Bcfe. There is 929 Bcfe in undeveloped proven reserves. The company also markets natural gas, oil and NGLs. It provides services to energy companies and utilities as well as industrial buyers of natural gas. Southwestern Energy Company was established in 1929. It is located in Spring, Texas.

西南能源公司是一家獨立的能源公司,專門從事美國天然和石油的勘探、開發和生產。該公司在勘探、生產和營銷領域開展業務。該公司專注於開發西弗吉尼亞州和賓夕法尼亞州的非常規天然氣儲備。截至2019年12月31日,它在阿巴拉契亞東北部擁有173,994英畝土地,在阿巴拉契亞西南部擁有287,693英畝土地。其已探明的石油和天然氣儲量,以及天然氣和天然氣儲量,估計為12,721 Bcfe。未開發的已探明儲量中有929個Bcfe。該公司還營銷天然氣、石油和NGL。它為能源公司和公用事業公司以及天然氣的工業買家提供服務。西南能源公司成立於1929年。它位於德克薩斯州的斯普林市。

NYSE ended the session with Southwestern Energy jumping 34.68% to $9.32 on Monday while NYSE jumped 1.78% to $15,942.62.

紐約證交所週一收盤時上漲34.68%,至9.32美元,紐約證交所上漲1.78%,至15,942.62美元。

Volume

Today's last reported volume for Southwestern Energy is 33228800 which is 5.33% below its average volume of 35101000.

今日西南能源最新公佈的成交量為33228800只,較35101000只的平均成交量低5.33%。

Southwestern Energy's last close was $9.32, 7.37% above its 52-week high of $8.68.

西南能源最新收盤報9.32美元,較52周高點8.68美元高出7.37%。

Southwestern Energy's Sales

西南能源的銷售額

Southwestern Energy's sales growth is 44.2% for the present quarter and a decline by 3.4% for the next. The company's growth estimates for the current quarter and the next is 57.9% and 29.2%, respectively.

西南能源本季度的銷售額增長了44.2%,下一季度下降了3.4%。該公司對當前季度和下一季度的增長預估分別為57.9%和29.2%。

Southwestern Energy's Revenue

西南能源的收入

Year-on-year quarterly revenue growth grew by 174.5%, now sitting on 8.54B for the twelve trailing months.

季度營收同比增長174.5%,連續12個月達到85.4億歐元。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Southwestern Energy's stock is considered to be oversold (<=20).

西南能源(Southwest Energy)的股票被認為處於超賣狀態。

Southwestern Energy's Stock Yearly Top and Bottom Value

西南能源股票年度最高值和最低值

Southwestern Energy's stock is valued at $9.32 at 17:32 EST, higher than its 52-week high of $8.68.

美國東部時間17:32,西南能源的股價為9.32美元,高於其52周高點8.68美元。

Southwestern Energy's Moving Average

西南能源的移動平均線

Southwestern Energy's worth is way above its 50-day moving average of $7.01 and way higher than its 200-day moving average of $5.39.

西南能源的市值遠高於50日移動均線切入位7.01美元,也遠高於200日移動均線切入位5.39美元。

More news about Southwestern Energy.

更多關於西南能源的新聞。

9. Merus N.V. (MRUS) – 32.55%

9.Merus N.V.(MRU)-32.55%

Merus N.V. is a Dutch clinical-stage immunooncology company that focuses on the development and discovery of bispecific antibodies therapeutics. The company's bispecific antibody candidates pipeline also includes Zenocutuzumab, (MCLA-128) which is currently in a Phase 2 clinical trial to treat patients with metastatic breast carcinoma. It will also be available in Phase 1/2, for pancreatic, lung, and other solid tumours. The company also has MCLA-117, which is currently in phase 1 clinical trials for patients with acute myeloidleukemia. MCLA-158 is also in phase 1 clinical trials for treatment of solid tumours. ONO-4685 is a Phase I clinical trial to treat autoimmune diseases. MCLA-129 is being researched and developed by Betta Pharmaceuticals Co. Ltd. MCLA-145 is being created in collaboration and Incyte Corporation. Clinical programs are also being offered to examine potential combinations therapies and indications. Merus N.V. is a partner in research and development of novel bispecific T-cell-redirecting antibodies through a license agreement and collaborations with Loxo Oncology at Lilly. It was founded in Utrecht in the Netherlands in 2003.

Merus N.V.是一家荷蘭臨牀階段的免疫腫瘤學公司,專注於雙功能抗體療法的開發和發現。該公司的雙特異性抗體候選產品線還包括Zenocutuzumab(MCLA-128),它目前處於治療轉移性乳腺癌患者的第二階段臨牀試驗。它也將在1/2期上市,用於胰腺、肺和其他實體腫瘤。該公司還擁有MCLA-117,目前正處於急性髓系白血病患者的第一階段臨牀試驗。MCLA-158也處於治療實體腫瘤的第一階段臨牀試驗。ONO-4685是治療自身免疫性疾病的I期臨牀試驗。MCLA-129正在由Betta製藥有限公司研發,MCLA-145正在與Collaboration和Incell公司合作開發。還提供臨牀計劃,以檢查潛在的組合、治療和適應症。Merus N.V.是通過許可協議和與禮來公司的Loxo腫瘤學合作研發新型雙特異性T細胞重定向抗體的合作伙伴。它於2003年在荷蘭烏得勒支成立。

NASDAQ ended the session with Merus N.V. jumping 32.55% to $18.53 on Monday while NASDAQ jumped 3.33% to $12,131.13.

納斯達克週一收盤時上漲32.55%,至18.53美元,納斯達克上漲3.33%,至12,131.13美元。

Volume

Today's last reported volume for Merus N.V. is 675952 which is 186.29% above its average volume of 236107.

今天,Merus N.V.最新報告的銷量為675952輛,比236107輛的平均銷量高出186.29%。

Merus N.V.'s last close was $18.53, 44% below its 52-week high of $33.09.

Merus N.V.最後收盤價為18.53美元,較52周高點33.09美元低44%。

Merus N.V.'s Sales

Merus N.V.的銷售額

Merus N.V.'s sales growth is a negative 15.6% for the ongoing quarter and a decline by 14.8% for the next. The company's growth estimates for the ongoing quarter is 14.1% and a drop 53.8% for the next.

Merus N.V.當前季度的銷售額增長為負15.6%,下一季度將下降14.8%。該公司對當前季度的增長預期為14.1%,下一季度將下降53.8%。

Merus N.V.'s Revenue

Merus N.V.的收入

Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 52.41M for the twelve trailing months.

季度收入同比增長39.6%,連續12個月增長至5241萬歐元。

Merus N.V.'s Stock Yearly Top and Bottom Value

Merus N.V.的股票年度最高和最低價值

Merus N.V.'s stock is valued at $18.53 at 17:32 EST, way under its 52-week high of $33.09 and way higher than its 52-week low of $13.47.

在美國東部時間17點32分,Merus N.V.的股價為18.53美元,遠低於33.09美元的52周高點,也遠高於13.47美元的52周低點。

Merus N.V.'s Moving Average

Merus N.V.的移動平均值

Merus N.V.'s value is way under its 50-day moving average of $22.09 and way under its 200-day moving average of $25.63.

Merus N.V.的價值遠低於其50日移動均線22.09美元,也遠低於其200日移動均線25.63美元。

More news about Merus N.V..

更多關於Merus N.V.的新聞。

10. Antero Resources (AR) – 27.21%

10.Antero Resources(AR)-27.21%

Antero Resources Corporation is an independent oil-and-natural gas company that acquires, investigates, develops and produces natural gaz, natural gas liquids and other oil properties throughout the United States. The company owned approximately 451,000 acres of net land in the Marcellus Shale's southwestern core and 91,000 acres of net land in the Utica Shale core as of December 31, 2019. The company also operated 324 mile of Marcellus Shale gas gathering pipelines, 17 compressor stations and 110 miles of Utica Shale low-pressure/high-pressure gathering pipelines. It also owns and operates 8 miles high-pressure pipelines and two compressor stations. It had proved natural gas reserves estimated at 18.9 trillion cubic yards, which included 11.5 trillion cubic meters of natural gas, 652 million barrels assumed-recovered ethane and 540 million barrels each of normal butane and propane; as well as 42 million barrels oil. Antero Resources Appalachian Corporation was the company's former name. In June 2013, it changed its name from Antero Resources Corporation to Antero Resources Corporation. Antero Resources Corporation was established in 2002. It is located in Denver, Colorado.

Antero Resources Corporation是一家獨立的石油和天然氣公司,在美國各地收購、調查、開發和生產天然氣、天然氣液體和其他石油資產。截至2019年12月31日,該公司在Marcellus頁巖西南部核心擁有約451,000英畝淨土地,在Utica頁巖核心擁有91,000英畝淨土地。該公司還運營着324英里的馬塞盧斯頁巖氣收集管道、17個壓縮機站和110英里的尤蒂卡頁巖低壓/高壓收集管道。它還擁有並運營着8英里的高壓管道和兩個壓縮機站。已探明的天然氣儲量估計為18.9萬億立方碼,其中包括11.5萬億立方米的天然氣,6.52億桶假定回收的乙烷,5.4億桶正丁烷和丙烷,以及4200萬桶石油。Antero Resources阿巴拉契亞公司是該公司的前身。2013年6月,它從Antero Resources Corporation更名為Antero Resources Corporation。Antero Resources Corporation成立於2002年。它位於科羅拉多州丹佛市。

NYSE ended the session with Antero Resources rising 27.21% to $44.74 on Monday while NYSE rose 1.78% to $15,942.62.

紐約證交所週一收盤上漲27.21%,至44.74美元,紐約證交所上漲1.78%,至15,942.62美元。

Volume

Today's last reported volume for Antero Resources is 6300230 which is 26.09% below its average volume of 8524230.

今天Antero Resources最新報告的成交量為6300230套,較8524230套的平均成交量低26.09%。

Antero Resources's last close was $44.74, 0.09% below its 52-week high of $44.78.

Antero Resources最新收盤報44.74美元,較52周高點44.78美元低0.09%。

The company's growth estimates for the ongoing quarter and the next is 1007.7% and 689.5%, respectively.

該公司對當前季度和下一季度的增長預期分別為1007.7%和689.5%。

Antero Resources's Revenue

Antero Resources的收入

Year-on-year quarterly revenue growth grew by 30.5%, now sitting on 6.93B for the twelve trailing months.

與去年同期相比,季度收入增長了30.5%,連續12個月達到6.93億歐元。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Antero Resources's stock is considered to be oversold (<=20).

Antero Resources的股票被認為是超賣(

Antero Resources's Stock Yearly Top and Bottom Value

Antero Resources的股票年度最高和最低價值

Antero Resources's stock is valued at $44.74 at 17:32 EST, under its 52-week high of $44.78 and way above its 52-week low of $10.91.

在美國東部時間17:32,Antero Resources的股價為44.74美元,低於44.78美元的52周高點,遠高於10.91美元的52周低點。

Antero Resources's Moving Average

Antero Resources的移動平均線

Antero Resources's worth is way higher than its 50-day moving average of $33.88 and way above its 200-day moving average of $22.63.

Antero Resources的價值遠高於50日移動均線切入位33.88美元,也遠高於200日移動均線切入位22.63美元。

More news about Antero Resources.

更多關於Antero Resources的新聞。

Most Active Losers Today

當今最活躍的失敗者

1. Aurora Cannabis (ACB) – -44.74%

1.Aurora Cannabis(ACB)--44.74%

NYSE ended the session with Aurora Cannabis dropping 44.74% to $1.68 on Monday while NYSE jumped 1.78% to $15,942.62.

週一,紐約證交所收盤時Aurora Cannabis下跌44.74%,至1.68美元,紐約證交所躍升1.78%,至15,942.62美元。

Volume

Today's last reported volume for Aurora Cannabis is 110527000 which is 1120.17% above its average volume of 9058310.

今天最新報告的極光大麻成交量為110527000只,比9058310只的平均成交量高出1120.17%。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Aurora Cannabis's stock is considered to be overbought (>=80).

Aurora Cannabis的股票被認為是超買(>=80)。

Previous days news about Aurora Cannabis

前幾天關於Aurora Cannabis的新聞

  • Aurora cannabis upsizes bought deal financing. According to Benzinga on Friday, 27 May, "Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?"
  • 奧羅拉大麻提高了收購交易融資的規模。根據Benzinga 5月27日星期五的報道,“儘管季度表現疲軟,但投資者為什麼要密切關注Aurora Cannabis的股票?”

More news about Aurora Cannabis.

更多關於奧羅拉·大麻的新聞。

2. Ironwood Investment Management, LLC (ACB) – -44.74%

2.Ironwood Investment Management,LLC(ACB)--44.74%

NYSE ended the session with Ironwood Investment Management, LLC dropping 44.74% to $1.68 on Monday while NYSE rose 1.78% to $15,942.62.

週一,紐約證交所Ironwood Investment Management收盤下跌44.74%,至1.68美元,紐約證交所上漲1.78%,至15,942.62美元。

Volume

Today's last reported volume for Ironwood Investment Management, LLC is 110527000 which is 1120.17% above its average volume of 9058310.

鐵木投資管理有限責任公司今天最新公佈的成交量為110527000只,比9058310只的平均成交量高出1120.17%。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Ironwood Investment Management, LLC's stock is considered to be overbought (>=80).

Ironwood Investment Management,LLC的股票被認為是超買(>=80)。

More news about Ironwood Investment Management, LLC.

更多有關鐵木投資管理公司的新聞。

3. Aurora Cannabis (ACB) – -44.74%

3.Aurora Cannabis(ACB)--44.74%

NYSE ended the session with Aurora Cannabis falling 44.74% to $1.68 on Monday while NYSE rose 1.78% to $15,942.62.

週一,紐約證交所收盤時Aurora Cannabis下跌44.74%,至1.68美元,紐約證交所上漲1.78%,至15,942.62美元。

Volume

Today's last reported volume for Aurora Cannabis is 110527000 which is 1120.17% above its average volume of 9058310.

今天最新報告的極光大麻成交量為110527000只,比9058310只的平均成交量高出1120.17%。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Aurora Cannabis's stock is considered to be overbought (>=80).

Aurora Cannabis的股票被認為是超買(>=80)。

Previous days news about Aurora Cannabis

前幾天關於Aurora Cannabis的新聞

  • Aurora cannabis upsizes bought deal financing. According to Benzinga on Friday, 27 May, "Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?"
  • 奧羅拉大麻提高了收購交易融資的規模。根據Benzinga 5月27日星期五的報道,“儘管季度表現疲軟,但投資者為什麼要密切關注Aurora Cannabis的股票?”

More news about Aurora Cannabis.

更多關於奧羅拉·大麻的新聞。

4. Ironwood Investment Management, LLC (ACB) – -44.74%

4.Ironwood Investment Management,LLC(ACB)--44.74%

NYSE ended the session with Ironwood Investment Management, LLC sliding 44.74% to $1.68 on Monday while NYSE jumped 1.78% to $15,942.62.

紐約證交所與Ironwood Investment Management一起收盤,LLC週一下跌44.74%,至1.68美元,紐約證交所躍升1.78%,至15,942.62美元。

Volume

Today's last reported volume for Ironwood Investment Management, LLC is 110527000 which is 1120.17% above its average volume of 9058310.

鐵木投資管理有限責任公司今天最新公佈的成交量為110527000只,比9058310只的平均成交量高出1120.17%。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Ironwood Investment Management, LLC's stock is considered to be overbought (>=80).

Ironwood Investment Management,LLC的股票被認為是超買(>=80)。

More news about Ironwood Investment Management, LLC.

更多有關鐵木投資管理公司的新聞。

5. Snap (SNAP) – -32.84%

5.Snap(SNAP)--32.84%

NYSE ended the session with Snap sliding 32.84% to $15.58 on Monday while NYSE rose 1.78% to $15,942.62.

紐約證交所週一收盤時下跌32.84%,至15.58美元,紐約證交所上漲1.78%,至15,942.62美元。

Volume

Today's last reported volume for Snap is 66159100 which is 80.31% above its average volume of 36691800.

今天Snap的最新成交量為66159100,比36691800的平均成交量高出80.31%。

Snap's last close was $15.58, 81.31% under its 52-week high of $83.34.

Snap最新收盤報15.58美元,較52周高點83.34美元低81.31%。

The company's growth estimates for the present quarter and the next is a negative 80% and a negative 41.2%, respectively.

該公司對當前季度和下一季度的增長預期分別為負80%和負41.2%。

Snap's Revenue

Snap的收入

Year-on-year quarterly revenue growth grew by 38.1%, now sitting on 4.41B for the twelve trailing months.

與去年同期相比,季度收入增長了38.1%,連續12個月達到44.1億美元。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Snap's stock is considered to be oversold (<=20).

Snap的股票被認為是超賣(

Snap's Stock Yearly Top and Bottom Value

Snap的股票年度最高和最低值

Snap's stock is valued at $15.58 at 17:32 EST, way below its 52-week low of $20.95.

美國東部時間17:32,Snap的股價為15.58美元,遠低於52周低點20.95美元。

Snap's Moving Average

Snap移動平均線

Snap's value is way below its 50-day moving average of $30.98 and way under its 200-day moving average of $48.94.

Snap的價值遠低於50日移動均線切入位30.98美元,也遠低於200日移動均線切入位48.94美元。

More news about Snap.

更多關於Snap的新聞。

6. Liquidia Technologies (LQDA) – -29.58%

6.Liqudia Technologies(LQDA)--29.58%

Liquidia Corporation is a biopharmaceutical firm that develops and manufactures products to meet unmet medical needs. LIQ861, an oral dry powder formulation treprostinil to treat pulmonary arterial hypertension, and LIQ865, which is a sustained-release formulation bupivacaine to relieve local pain after surgery are two of its product candidates. Generic treprostinil injection is also distributed by the company in the United States. Liquidia Corporation was established in 2004 in Morrisville in North Carolina.

Liqudia公司是一家生物製藥公司,開發和製造滿足未得到滿足的醫療需求的產品。LIQ861是一種治療肺動脈高壓的口服乾粉製劑曲普替尼,LIQ865是一種用於緩解術後局部疼痛的布比卡因緩釋製劑。該公司還在美國分銷仿製藥曲普替尼注射劑。Liqudia公司於2004年在北卡羅來納州的莫里斯維爾成立。

NASDAQ ended the session with Liquidia Technologies dropping 29.58% to $4.07 on Monday, after three sequential sessions in a row of gains. NASDAQ jumped 3.33% to $12,131.13, after three sequential sessions in a row of gains, on what was a very bullish trend exchanging session today.

納斯達克在連續三個交易日上漲後,週一收盤時下跌29.58%,至4.07美元。納斯達克在連續三個交易日上漲後,躍升3.33%,至12,131.13美元,這是一個非常看漲的趨勢交流時段。

Volume

Today's last reported volume for Liquidia Technologies is 872023 which is 4.42% above its average volume of 835084.

今天,Liqudia Technologies最新公佈的成交量為872023台,比835084台的平均成交量高出4.42%。

Liquidia Technologies's last close was $4.07, 47.69% under its 52-week high of $7.78.

Liqudia Technologies最後收盤價為4.07美元,較其52周高點7.78美元低47.69%。

Liquidia Technologies's Sales

Liqudia Technologies的銷售額

Liquidia Technologies's sales growth is 103.5% for the present quarter and 17.6% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 69.2% and a negative 71.4%, respectively.

Liqudia Technologies本季度的銷售額增長率為103.5%,下一季度為17.6%。該公司對當前季度和下一季度的增長預期分別為負69.2%和負71.4%。

Liquidia Technologies's Revenue

Liqudia Technologies的收入

Year-on-year quarterly revenue growth grew by 13.2%, now sitting on 13.26M for the twelve trailing months.

季度營收同比增長13.2%,連續12個月增長1326萬。

Liquidia Technologies's Stock Yearly Top and Bottom Value

Liqudia Technologies的股票年度最高和最低價值

Liquidia Technologies's stock is valued at $4.07 at 17:32 EST, way under its 52-week high of $7.78 and way higher than its 52-week low of $2.25.

在美國東部時間17點32分,Liqudia Technologies的股價為4.07美元,遠低於7.78美元的52周高點,也遠高於2.25美元的52周低點。

Liquidia Technologies's Moving Average

Liqudia Technologies的移動平均線

Liquidia Technologies's worth is way below its 50-day moving average of $5.91 and way under its 200-day moving average of $4.80.

Liqudia Technologies的市值遠低於5.91美元的50日移動均線,也遠低於4.80美元的200日移動均線。

More news about Liquidia Technologies.

更多關於Liqudia Technologies的新聞。

7. NeuroMetrix (NURO) – -25.45%

7.Neurometrix(NURO)--25.45%

NeuroMetrix, Inc., is a healthcare company that develops and markets products to detect, diagnose, and monitor peripheral nerve and spine cord disorders. It develops neuro-stimulation therapy devices for wear and points-of-care diagnostic tests for neuropathy to treat chronic conditions such as diabetes, chronic pain and sleep disorders. The company's most popular products are Quell which is a wearable device that provides relief from chronic, intractable, pain. This includes nerve pain caused by diabetes or lower back pain; DPNCheck, which can be used to diagnose systemic neuropathies such as diabetic peripheral nerve neuropathy. ADVANCE, an online platform, allows for traditional nerve conduction studies to be performed; and SENSUS. A pain therapy device that uses transcutaneous electrical nerve stimulation to relieve chronic, intractable, pain. It sells its products to customers, retailers, TV promotors, doctors, nurses, and other health professionals. The company operates across the United States and Mexico, as well as in Europe, Japan China, China, Middle East, Mexico, and China. GlaxoSmithKline has been a strategic partner of the company. NeuroMetrix, Inc., was established in 1996. It is located in Woburn, Massachusetts.

Neurometrix,Inc.是一家醫療保健公司,開發和營銷用於檢測、診斷和監測周圍神經和脊髓疾病的產品。它開發用於穿戴的神經刺激治療設備和神經病變的護理點診斷測試,以治療糖尿病、慢性疼痛和睡眠障礙等慢性疾病。該公司最受歡迎的產品是Quell,這是一款可穿戴設備,可以緩解慢性、頑固的疼痛。這包括糖尿病或下腰痛引起的神經疼痛;DPNCheck,可用於診斷全身神經病變,如糖尿病周圍神經病變。在線平臺Advance允許進行傳統的神經傳導研究;以及人口普查。一種疼痛治療裝置,使用經皮神經電刺激來緩解慢性、頑固性疼痛。它將其產品銷售給客户、零售商、電視推廣員、醫生、護士和其他健康專業人員。該公司業務遍及美國和墨西哥,以及歐洲、日本、中國、中東、墨西哥和中國。葛蘭素史克一直是該公司的戰略合作伙伴。Neurometrix,Inc.成立於1996年。它位於馬薩諸塞州的沃本。

NASDAQ ended the session with NeuroMetrix sliding 25.45% to $4.10 on Monday while NASDAQ jumped 3.33% to $12,131.13.

週一收盤時,納斯達克下跌25.45%,至4.10美元,納斯達克上漲3.33%,至12,131.13美元。

Volume

Today's last reported volume for NeuroMetrix is 420499 which is 73.89% below its average volume of 1610720.

今天,NeuroMetrix的最新成交量為420499只,比1610720只的平均成交量低了73.89%。

NeuroMetrix's last close was $4.10, 89.42% below its 52-week high of $38.75.

Neurometrix最新收盤報4.10美元,較52周高點38.75美元低89.42%。

NeuroMetrix's Revenue

Neurometrix的收入

Year-on-year quarterly revenue growth grew by 6.8%, now sitting on 8.4M for the twelve trailing months.

與去年同期相比,季度收入增長了6.8%,連續12個月增長840萬。

NeuroMetrix's Stock Yearly Top and Bottom Value

Neurometrix的股票年度最高和最低價值

NeuroMetrix's stock is valued at $4.10 at 17:32 EST, way below its 52-week high of $38.75 and way above its 52-week low of $2.70.

美國東部時間17:32,Neurometrix的股價為4.10美元,遠低於38.75美元的52周高點,遠高於2.70美元的52周低點。

NeuroMetrix's Moving Average

Neurometrix移動平均線

NeuroMetrix's worth is above its 50-day moving average of $3.82 and way below its 200-day moving average of $6.44.

Neurometrix的價值高於50日移動均線3.82美元,遠低於200日移動均線6.44美元。

More news about NeuroMetrix.

更多有關NeuroMetrix的新聞。

8. Medigus Ltd. (MDGSW) – -22.93%

8.邁迪格斯有限公司--22.93%

NASDAQ ended the session with Medigus Ltd. falling 22.93% to $0.24 on Monday, after five successive sessions in a row of losses. NASDAQ jumped 3.33% to $12,131.13, after three consecutive sessions in a row of gains, on what was a very bullish trend exchanging session today.

納斯達克週一收盤下跌22.93%,至0.24美元,此前該公司曾連續五個交易日下跌。納斯達克在連續三個交易日上漲後,躍升3.33%,至12,131.13美元,這是一個非常看漲的趨勢交流時段。

Medigus Ltd.'s last close was $0.24, 26.83% under its 52-week high of $0.33.

Medigus Ltd.收盤報0.24美元,較0.33美元的52周高點低26.83%。

Medigus Ltd.'s Stock Yearly Top and Bottom Value

梅迪格斯股份有限公司股票年度最高和最低價值

Medigus Ltd.'s stock is valued at $0.24 at 17:32 EST, way under its 52-week high of $0.33 and higher than its 52-week low of $0.22.

美國東部時間17:32,Medigus Ltd.的股價為0.24美元,遠低於0.33美元的52周高點,也高於0.22美元的52周低點。

More news about Medigus Ltd..

更多關於Medigus Ltd.的新聞。

9. NeuroBo Pharmaceuticals (NRBO) – -22.21%

9.NeuroBo製藥公司(NRBO)--22.21%

NeuroBo Pharmaceuticals, Inc., is a biotechnology company in clinical stage that offers therapies for neurodegenerative, coronavirus, and other cardiometabolic disorders. Its therapeutics program includes ANA001, an oral niclosamide formulation that has been successfully tested in Phase 2 of a clinical trial for patients suffering from moderate coronavirus diseases (COVID-19); NB-01 to manage painful diabetic neuropathy and to modify neurodegenerative disease progressions associated with protein malfunctions; Gemcabene which is an acute indication of COVID-19. NeuroBo Pharmaceuticals, Inc., was established in 2017. It is located in Boston, Massachusetts.

NeuroBo製藥公司是一家處於臨牀階段的生物技術公司,提供治療神經退行性疾病、冠狀病毒和其他心臟代謝疾病的藥物。該公司的治療計劃包括:ANA001,這是一種口服氯硝柳胺製劑,已在針對中度冠狀病毒病(新冠肺炎)患者的第二階段臨牀試驗中成功測試;NB-01,用於治療疼痛的糖尿病神經病變和改變與蛋白質故障相關的神經退行性疾病的進展;GemCabene,新冠肺炎的急性適應症。NeuroBo製藥公司成立於2017年。它位於馬薩諸塞州的波士頓。

NASDAQ ended the session with NeuroBo Pharmaceuticals falling 22.21% to $0.43 on Monday, following the last session's upward trend. NASDAQ rose 3.33% to $12,131.13, after three sequential sessions in a row of gains, on what was a very up trend exchanging session today.

納斯達克週一收盤時下跌22.21%,至0.43美元,延續上一交易日的上漲趨勢。納斯達克在連續三個交易日上漲後,今日上漲3.33%,至12,131.13美元,這是一個非常上漲的趨勢交流時段。

Volume

Today's last reported volume for NeuroBo Pharmaceuticals is 94326 which is 53.33% below its average volume of 202128.

今日公佈的NeuroBo PharmPharmticals最新成交量為94326只,較202128只的平均成交量低53.33%。

NeuroBo Pharmaceuticals's last close was $0.43, 93.44% under its 52-week high of $6.57.

NeuroBo PharmPharmticals最新收盤報0.43美元,較6.57美元的52周高點低93.44%。

NeuroBo Pharmaceuticals's Stock Yearly Top and Bottom Value

NeuroBo製藥公司股票年度最高和最低值

NeuroBo Pharmaceuticals's stock is valued at $0.43 at 17:32 EST, way under its 52-week high of $6.57 and way higher than its 52-week low of $0.38.

美國東部時間17:32,NeuroBo PharmPharmticals的股價為0.43美元,遠低於6.57美元的52周高點,也遠高於0.38美元的52周低點。

NeuroBo Pharmaceuticals's Moving Average

NeuroBo製藥公司的移動平均線

NeuroBo Pharmaceuticals's value is way below its 50-day moving average of $0.72 and way under its 200-day moving average of $1.65.

NeuroBo PharmPharmticals的市值遠低於50日移動均線0.72美元,也遠低於200日移動均線1.65美元。

More news about NeuroBo Pharmaceuticals.

更多有關NeuroBo製藥公司的新聞。

10. Canopy Growth (CGC) – -16.87%

10.冠層生長(CGC)--16.87%

NASDAQ ended the session with Canopy Growth sliding 16.87% to $4.88 on Monday, after three sequential sessions in a row of losses. NASDAQ rose 3.33% to $12,131.13, after three consecutive sessions in a row of gains, on what was a very up trend exchanging session today.

納斯達克在連續三個交易日下跌後,週一收盤時股價下跌16.87%,至4.88美元。納斯達克在連續三個交易日上漲後,今天上漲3.33%,至12,131.13美元,這是一個非常上漲的趨勢交流時段。

Volume

Today's last reported volume for Canopy Growth is 16635100 which is 124.69% above its average volume of 7403360.

今天最新報告的樹冠生長量為16635100棵,比7403360棵的平均樹冠生長量高124.69%。

Canopy Growth's last close was $4.88, 91.36% under its 52-week high of $56.50.

Canopy Growth的最後收盤價為4.88美元,較52周高點56.50美元低91.36%。

Canopy Growth's Revenue

冠層增長的收入

Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 572.44M for the twelve trailing months.

與去年同期相比,季度收入增長了23.4%,連續12個月增長5.7244億。

Stock Price Classification

股票價格分類

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

根據隨機振盪器,一個有用的超買和超賣狀態指標,

Canopy Growth's stock is considered to be overbought (>=80).

Canopy Growth的股票被認為是超買(>=80)。

Canopy Growth's Stock Yearly Top and Bottom Value

冠層生長量年最高值和最低值

Canopy Growth's stock is valued at $4.88 at 17:32 EST, way under its 52-week low of $9.54.

截至美國東部時間17:32,Canopy Growth的股價為4.88美元,遠低於9.54美元的52周低點。

Canopy Growth's Moving Average

冠層生長量的移動平均值

Canopy Growth's worth is way under its 50-day moving average of $12.63 and way below its 200-day moving average of $20.75.

Canopy Growth的價值遠低於50日移動均線12.63美元,也遠低於200日移動均線20.75美元。

Previous days news about Canopy Growth

前幾天有關樹冠生長的新聞

  • Canopy growth shares drop on wider-than-expected loss. According to MarketWatch on Friday, 27 May, "In FY2023, we are focused on executing our path to profitability in Canada, while we continue to invest in high potential opportunities — particularly in BioSteel, and further developing our U.S. THC ecosystem, which we believe remains significantly under-appreciated by the market." Prior to Friday's trades, shares of Canopy Growth are down 35.5% in 2022 compared to a drop of 25% by the Nasdaq and a loss of 41.9% by the Cannabis ETF .", "Looking ahead, Canopy Growth expects to generate positive adjusted Ebitda in fiscal year 2024, excluding investments in BioSteel drinks and its U.S. THC businesses. "
  • Canopy growth stock earnings: CGC shares plummet on major earnings miss. According to FXStreet on Friday, 27 May, "This level may be months off as Canopy Growth will require some positivity around earnings in order to provoke any type of rally."
  • Canopy Growth股價下跌,跌幅超出預期。根據MarketWatch週五(5月27日)的報告,“在2023財年,我們專注於在加拿大實現盈利,同時我們繼續投資於高潛力的機會,特別是在BioSteel,並進一步發展我們在美國的THC生態系統,我們認為市場仍然嚴重低估了這一生態系統。”在週五的交易之前,Canopy Growth的股價在2022年下跌了35.5%,相比之下,納斯達克下跌了25%,大麻ETF下跌了41.9%。展望未來,Canopy Growth預計2024財年調整後的EBITDA將為正,不包括對BioSteel飲料及其美國THC業務的投資。“
  • Canopy Growth股票收益:由於重大收益未達到預期,CGC股價暴跌。根據FXStreet週五(5月27日)的數據,“這一水平可能還需要幾個月的時間,因為Canopy的增長需要圍繞收益的一些積極因素,才能刺激任何類型的反彈。”

More news about Canopy Growth.

更多關於樹冠生長的新聞。

Stay up to date with our winners and losers daily report

隨時關注我們的贏家和輸家每日報告

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論